title: The effects of PDL-Ig on collagen-induced arthritis.
abstract: Programmed death ligand (PDL) is a new member of the B7 family of costimulatory molecules that specifically interacts with programmed death 1 (PD-1) expressed on activated T cells, B cells, and myeloid cells. Collagen II (CII)-induced arthritis (CIA) is an experimental model of arthritis that has been used to dissect the pathogenesis of human rheumatoid arthritis. In this study, we have investigated the effects of PDL-Ig on CIA. Administration of PDL-Ig significantly ameliorated the disease as assessed by clinical arthritis score and histology in the joints. Expression of proinflammatory cytokines, such as IL-17 and IL-23, in the serum was reduced by PDL-Ig treatment. These results showed a beneficial effect of PDL-Ig on CIA through anti-inflammatory actions and inhibition of cell proliferation in response to CII, suggesting that the PD-1-PDL pathway may be involved in the pathogenesis of CIA, and thus PDL-Ig may be a useful therapy for the improvement of human rheumatoid arthritis.
authors.affiliation: Department of Immunology, Tongji Medical College of Huazhong University of Science and Technology, 430030 Wuhan, China. ghw7206@163.com
authors.forename: Guohua
authors.initials: G
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Hu
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
authors.forename: Guanxin
authors.initials: G
authors.lastname: Shen
authors.forename: Xiongwen
authors.initials: X
authors.lastname: Wu
mesh_terms: D000818:Animals; D000954:Antigens, Surface / Q000502:physiology; D051017:Apoptosis Regulatory Proteins / Q000502:physiology; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018122:B7-1 Antigen / Q000627:therapeutic use*; D049109:Cell Proliferation; D020381:Interleukin-17 / Q000096:biosynthesis; D053759:Interleukin-23 / Q000096:biosynthesis; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D061026:Programmed Cell Death 1 Receptor; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D000954:Antigens, Surface; D051017:Apoptosis Regulatory Proteins; D018122:B7-1 Antigen; D020381:Interleukin-17; D053759:Interleukin-23; C491383:Pdcd1 protein, mouse; D061026:Programmed Cell Death 1 Receptor; D011993:Recombinant Fusion Proteins